Product
Eureka
For R&D, Eureka makes reading and utilizing patents & technical documents easy.
Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
30 results about "CD64" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
CD64 (Cluster of Differentiation 64) is a type of integral membrane glycoprotein known as an Fc receptor that binds monomeric IgG-type antibodies with high affinity. It is more commonly known as Fc-gamma receptor 1 (FcγRI). After binding IgG, CD64 interacts with an accessory chain known as the common γ chain (γ chain), which possesses an ITAM motif that is necessary for triggering cellular activation.
Combined reagent for detecting acute myelocytic leukemia cells and system thereof
ActiveCN109655616AWide coverageThere is no problem of reciprocal inhibition of expressionMaterial analysisCD33CD15
The invention relates to a combined reagent for detecting acute myelocytic leukemia cells and a system thereof, wherein the combined reagent and the system thereof belong to the field of medical technology. The combined reagent comprises at least one selected from the following antibody combinations: a first antibody combination which comprises CD38, CD13, CD34, CD117, CD33, CD19, HLA-DR and CD45antibodies; a second antibody combination which comprises CD38, CD64, CD34, CD123, CD56, CD14, HLA-DR and CD45 antibodies; and a third antibody combination which comprises CD38, CD7, CD34, CD5, CD11b,CD15 and CD45 antibodies. The antibody combinations of the invention cover the expression marks of three systems of granulocyte, single cell and lymphocyte. A normal antibody expression mode is established. Tumor cells can be identified maximally. Furthermore, through a large number of experiment data, the antibodies in each combination have no problem of mutual expression inhibition. FurthermoreAML-MRD can be comprehensively and quickly detected with high sensitivity through multi-parameter flow type cell analysis.
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT
Method for efficiently amplifying NK cells
InactiveCN106754730AEnhanced lethalityEnhanced ADCC effectBlood/immune system cellsCell culture active agentsNatural Killer Cell Inhibitory ReceptorsCD86
The invention discloses a method for efficiently amplifying NK cells, in particular to a method for efficiently amplifying NK cells using K562 engineered cells of high expression membrane proteins CD19, CD137L, CD86, CD64 and transmembrane protein IL- 21 and combining with human IL-2 mutants. The method has the advantages of simple operation, low cost, large number of obtained NK cells, high purity and good killing effect; the method is suitable for large-scale preparation of the NK cells and lays a good foundation for the application of NK cell adoptive immunotherapy in clinical practice.
Owner:SHANGHAI BIOMED UNION BIOTECHNOLOGY CO LTD
Software integrated cytometric assay for quantification of the human polymorphonuclear leukocyte fctri receptor (CD64)
ActiveUS20090117605A1Easy diagnosisImprovement in therapeutic monitoringBioreactor/fermenter combinationsBiological substance pretreatmentsAssayFluorescence
The invention relates a method of quantifying CD64 and CD163 expression in leukocytes and, specifically to a kit for use with a flow cytometer including a suspension of quantitative fluorescent microbead standards, fluorescent labeled antibodies directed to CD64 and CD163, and analytical software. The software is used to take information on the microbead suspension and fluorescent labeled antibodies from a flow cytometer and analyse data, smooth curves, calculate new parameters, provide quality control measures and notify of expiration of the assay system.
Owner:TRILLIUM DIAGNOSTICS
Neutrophile granulocyte CD64 determination method for clinical infectious diseases
PendingCN110823789AEliminate the effects ofImprove standardizationIndividual particle analysisFluorescence/phosphorescenceLymphocyteNeutrophil granulocyte
The invention relates to the technical field of neutrophile granulocyte determination, in particular to a neutrophile granulocyte CD64 determination method for clinical infectious diseases. The methodcomprises the following steps of: collecting a sample; carrying out flow detection; and performing CD64 index calculation: the formula is as follows: CD64 index=(neutrophile granulocyte CD64 fluorescence intensity-lymphocyte CD64 fluorescence intensity) / (monocyte CD64 fluorescence intensity-lymphocyte CD64 fluorescence intensity)-(neutrophile granulocyte CD64 fluorescence intensity-lymphocyte CD64 fluorescence intensity). In the neutrophile granulocyte CD64 determination method for clinical infectious diseases, the fluorescence intensity of mononuclear cells is used as a positive control, andthe fluorescence intensity of lymphocytes is used as a negative control, so that the influence of factors such as instruments, reagents, voltage and the like on results can be eliminated, and the standardization of the results is facilitated.
Owner:徐州市儿童医院
NK trophoblast cell and application thereof
PendingCN112725284AHigh cytotoxic activityRapid expansionAntibody mimetics/scaffoldsNucleic acid vectorNatural Killer Cell Inhibitory ReceptorsCD86
The invention provides an NK trophoblast cell and an application thereof, the NK trophoblast cell expresses a cytokine composition, and the cytokine composition comprises CD86, CD19, IL-21, CD137L and CD64; wherein the CD86 comprises an amino acid sequence as shown in SEQ ID No. 1. The invention also provides a recombinant vector, a recombinant lentivirus, a preparation method of the NK trophoblastic cell and an NK cell culture medium. The recombinant lentivirus is obtained by constructing the recombinant vector and packaging, and then introduced into the genome of the host cell, so that the prepared NK trophoblastic cell can continuously secrete the related protein for stimulating the proliferation and differentiation of the NK cell, the high-efficiency and low-cost amplification of the NK cell is realized, the preparation method is simple and efficient, and the application prospect is wide.
Owner:HENAN HUALONG BIOLOGICAL TECH
Method for in-vitro large-scale induction of NK cell expansion
ActiveCN110331132AHighly toxicObvious lethal effectCulture processBlood/immune system cellsAntigenNatural Killer Cell Inhibitory Receptors
The invention relates to a method for in-vitro large-scale induction of NK cell expansion, and belongs to the technical field of biology. According to the invention, the constructed novel artificial antigen presenting cell CD86 CD64 mIL-15-aAPC is taken as an expanded feeder cell, NK cells are directly expanded from peripheral blood lymphocytes, and the NK cells expanded by the method has the advantages of good proliferation, high purity, strong cytotoxicity and obvious tumor cell killing effect. The invention solves the problems of limited number of cell expansion, low expression level of surface antigen CD3- / CD56+ and low cell killing activity faced by traditional culture methods, and can meet the clinical requirement on NK cells.
Owner:侯宗柳
A method for stimulating the efficient proliferation of peripheral blood γδt cells in vitro and its application
ActiveCN105112370BIntact Antitumor CytotoxicityMammal material medical ingredientsBlood/immune system cellsIn vitro stimulationAntiendomysial antibodies
Owner:杭州朔溪生物医药有限公司
Engineered cell for activating NK-like cell, and preparation method and application of engineered cell
PendingCN112626028AImprove proliferative abilityImprove tumor killing abilityMicroorganism based processesMammal material medical ingredientsCD86Cell Membrane Proteins
The invention provides an engineered cell for activating a NK-like cell, and a preparation method and application of the engineered cell. The engineered cell is a mammalian cell for expressing membrane proteins MICA, IL-21, CD64 and CD86. The engineered cell disclosed by the invention expresses and activates the membrane protein of the NK-like cell; the amplification capacity of the NK-like cell and the toxicity of tumour cells are improved; and a strategy for standardizing in-vitro amplification of the NK-like cell is provided.
Owner:广东昭泰细胞生物科技有限公司
NK cell as well as preparation method and application thereof
PendingCN112725273AIncrease the number ofHigh activityGenetically modified cellsAntiviralsNatural Killer Cell Inhibitory ReceptorsCD86
The invention relates to an NK cell as well as a preparation method and an application thereof. The preparation method comprises the following steps: inducing and culturing umbilical cord blood mononuclear cells by utilizing engineered K562 cells to obtain the NK cells. The engineered K562 cells express cytokines CD19, CD86, IL21, CD64 and CD137L, umbilical cord blood mononuclear cells can be efficiently amplified and activated, the prepared NK cells have high amplification quantity and cell viability, the use amount of the engineered K562 cells is low, and the cost can be effectively reduced.
Owner:HENAN HUALONG BIOLOGICAL TECH
Antibody composition and its application in screening myeloid diseases and detecting immune checkpoints
ActiveCN112630438BImprove survival rateHigh incidenceDisease diagnosisIndividual particle analysisDiseaseAnti antibody
Owner:信纳克(北京)生化标志物检测医学研究有限责任公司
Flow type door closing method and application
ActiveCN114441419AReduce overlapThe gate result is accurateIndividual particle analysisDiseaseWhite blood cell
The invention discloses a flow type circling method which comprises the following steps: detecting a blood sample co-incubated by a CD45 antibody, a CD14 antibody and a CD64 antibody by using lateral scattered light and CD45 fluorescence, and circling white blood cells in the sample; respectively circling portal neutrophils and lymphocytes in the circled leukocytes by using CD45 fluorescence; in the white blood cells of the enclosure, CD14 fluorescent enclosure mononuclear cells are used. The invention also discloses application of the CD45 antibody and a mixture of the CD14 antibody and the CD64 antibody in preparation of infectious disease diagnosis products, wherein high expression of the CD64 in neutrophile granulocytes is used as an indication of the disease. The flow type door circling method does not excessively depend on experience of technicians, detection consistency is guaranteed, and the door circling mode is more accurate, simpler and clearer. After lymphocytes, monocytes and neutrophils are accurately circled out respectively, whether infectious diseases exist or not can be diagnosed according to the expression of CD64 on the neutrophils.
Owner:杭州翔宇医学检验实验室有限公司
Recombinant multi-stimulus molecular cell, preparation method and application in NKT cell amplification thereof
ActiveCN103937747AEasy to manufactureLow costBlood/immune system cellsVector-based foreign material introductionForeign proteinTumor cells
The invention discloses a recombinant multi-stimulus molecular cell ME64 / CD137L / mIL-18, a preparation method and application in NKT (natural killer T) cell in-vitro amplification thereof. The preparation method comprises: taking an MEG-01 cell as a carrier, transfecting a CD64 eukaryotic expression vector, and conducting screening and sorting to obtain an ME64 cell; then preparing an eukaryotic expression vector expressing both CD137L and mIL-18; and transfecting the ME64 cell with the vector, thus obtaining the ME64 / CD137L / mIL-18 cell. Being easy for large-scale preparation, the cell has the advantages of low cost and good repeatability, and can stably express foreign protein. The cell can stimulate mass amplification of the NKT cell when it is used for NKT cell in-vitro amplification, and can increase proliferation frequency of the NKT cell and tumor cell killing toxicity.
Owner:COBAXER BIOTECH
Artificial antigen-presenting cells and their construction methods and their application in the expansion of chimeric antigen receptor T cells
The invention relates to an artificial antigen-presenting cell, its construction method and its application in the expansion of chimeric antigen receptor T cells, belonging to the field of medical technology. The present invention uses K562 cells as a carrier, and stably expresses CD137L, CD86, CD64, membrane-immobilized interleukin 15 and CD19 on the surface of the cell membrane through lentiviral transfection, and constructs a novel artificial antigen-presenting cell CD137L CD86 CD64 mIL-15 CD19-K562 cells. This serves as an expanded feeder cell to directly expand CD19 CAR‑T cells from peripheral blood lymphocytes. Flow cytometric sorting showed that the established aAPC surface molecular markers were constructed. The aAPC-expanded CD19 CAR-T cells proliferate well, have high purity, strong cytotoxicity, and have obvious tumor cell killing effect.
Owner:YANAN HOSPITAL OF KUNMING CITY
Combination reagent and system for detecting acute myeloid leukemia cells
ActiveCN109655616BWide coverageThere is no problem of reciprocal inhibition of expressionMaterial analysisCD5Antibody expression
Owner:GUANGZHOU KINGMED DIAGNOSTICS CENT
A method for large-scale induction of NK cell expansion in vitro
ActiveCN110331132BHigh purityStrong cytotoxicityCulture processBlood/immune system cellsAntigenNatural Killer Cell Inhibitory Receptors
Owner:YANAN HOSPITAL OF KUNMING CITY
Application of EPO (erythropoietin) analogue in preparation of medicine for treating sepsis
InactiveCN112741895AHigh expressionImprove survival rateAntibacterial agentsPeptide/protein ingredientsDiseaseTissue repair
The invention relates to the technical field of biological medicines, in particular to application of an EPO analogue in preparation of a medicine for treating sepsis. The EPO analogue is an EPO-sourced micro-molecule polypeptide, and the structural formula of the EPO analogue is as follows: Gln Glu GlnLeu Glu Arg Ala Leu Asn Ser Ser; the EPO-sourced micro-molecule polypeptide can be compounded with LPS (lipopolysaccharide) to treat sepsis, and can be used as an endotoxin-tolerant accelerant for macrophage generation, an inhibitor for gene expression of proinflammatory factor, an accelerant for gene expression of antibacterial and tissue repair molecules, an inhibitor of chemotactic factors CCL3 and CCL4, and an accelerant of CD64, MARCO, C-type lectin domain family 4 member A, CNLP, formyl peptide receptor 1, acyloxyacyl hydrolase and ribonuclease T2. By activating the macrophage EPOR, expression of inflammatory factors of the macrophage can be inhibited, expression of antibacterial and tissue repair genes of the macrophage can be promoted, the survival rate of sepsis can be increased, the death rate can be reduced, and a new treatment thought is provided for treating various sepsis-related diseases.
Owner:ARMY MEDICAL UNIV
Trophoblast, preparation method thereof and application of trophoblast in massive rapid amplification of gamma delta T cells
ActiveCN111206052AAchieve multiplicationEasy to operateGenetically modified cellsNucleic acid vectorAntiendomysial antibodiesCD86
The invention relates to a trophoblast, a preparation method thereof and application of the trophoblast in massive rapid amplification of gamma delta T cells. The preparation method comprises the following steps: S1, constructing a pLenti-okt3-CD64-CD86-4.1BBL lentiviral plasmid vector; S2, packaging lentiviral particles by using the pLenti-okt3-CD64-CD86-4.1BBL plasmid vector; S3, preparing K562-okt3-CD64-CD86-4.1BBL trophoblast; S4, obtaining buffy coat cells of umbilical cord blood; and S5, carrying out in vitro amplification on gamma delta T cells of the umbilical cord blood. According tothe preparation method, an okt3 single-chain antibody is expressed on a trophoblast membrane through a CD8A transmembrane region, especially, the gamma delta T cells can be rapidly and massively amplified from the umbilical cord blood at low cost, the amplification multiple of the gamma delta T cells can reach about 10000 times after a 24-day amplification period, and the purity of the prepared gamma delta T cells can reach 90% or above. Compared with stimulation by a soluble okt3 antibody, the membrane-bound okt3 has the amplification multiple over 2 times to the gamma delta T cells, and hasa good clinical application prospect.
Owner:中邦干细胞科技有限公司
Variants with fc fragment having an increased affinity for fcrn and an increased affinity for at least one receptor of the fc fragment
PendingUS20210214434A1Improve translation speedIncreasing the final titre (Carton, JSenses disorderNervous disorderGeneticsFc fragment
Disclosed is a variant of a parent polypeptide including an Fc fragment, the variant having an increased affinity for the FcRn receptor, and an increased affinity for at least one receptor of the Fc fragment (FcR) chosen from the FcγRI (CD64), FcγRIIIa (CD16a) and FcγRIIa (CD32a) receptors, relative to that of the parent polypeptide, characterised in that it includes: (i) the four mutations 334N, 352S, 378V and 397M; and (ii) at least one mutation chosen from 434Y, 434S, 226G, P228L, P228R, 230S, 230T, 230L, 241L, 264E, 307P, 315D, 330V, 362R, 389T and 389K; the numbering being that of the EU index or the Kabat equivalent.
Owner:LABE FR DU FRACTIONNEMENT & DES BIOTECH SA
Induced T-to-natural killer feeder cell as well as preparation method and application thereof
PendingCN112592898ASignificantly promote amplificationSignificant activityNucleic acid vectorBlood/immune system cellsReprogrammingCD86
The invention provides an induced T-to-natural killer feeder cell as well as a preparation method and application thereof. The induced T-to-natural killer feeder cell expresses membrane proteins IL-12, CD19, CD64 and CD86. The induced T-to-natural killer feeder cell is constructed by adopting combination of the IL-12, the CD19, the CD64 and the CD86 for induced T-to-natural killer cell culture, and the obtained induced T-to-natural killer cell is high in quantity increasing speed, remarkable in tumor killing capacity and good in functional stability, and has important application prospects inthe field of immunotherapy.
Owner:广东昭泰细胞生物科技有限公司
Cell chip as well as detection method and application of cell chip for bacterial infection
PendingCN114324875AStrong specificityHigh sensitivityMaterial analysis by observing effect on chemical indicatorAbsolute neutrophil countBiology
The invention belongs to the technical field of biology, and particularly relates to a cell chip and a detection method and application thereof for bacterial infection.The cell chip comprises an aldehyde group modified glass slide, the surface of the glass slide is divided into at least one reaction area, a polyclonal secondary antibody is fixed in the reaction area, the polyclonal secondary antibody is connected with a CD64 monoclonal primary antibody, and the CD64 monoclonal primary antibody is connected with a CD64 monoclonal secondary antibody. The preparation method of the cell chip for bacterial infection detection comprises the following steps: dropwise adding a mixed solution of a polyclonal secondary antibody and a CD64 monoclonal primary antibody prepared according to a mass ratio of 1: (0.2-4) into a reaction area on the surface of a positioning glass slide, incubating for 30-60 minutes, then leaching and soaking with a buffer solution, and finally drying to obtain the cell chip. The invention aims to provide a cell chip which is low in cost and simple and convenient to operate and can be used for absolute counting of CD64 neutrophils. A CD64 biological marker which is high in specificity, high in sensitivity and capable of being continuously detected is adopted in the cell chip.
Owner:何骏杰
Nucleic acid aptamer for detecting microglial cells and application of nucleic acid aptamer
PendingCN114836425ASmall molecular weightUnique stem-loop structureSpecial deliveryDisease diagnosisActivated microglial cellAptamer
According to the nucleic acid aptamer for detecting the microglial cells and the application, the prepared nucleic acid aptamer has a unique stem-loop structure, and it is found through flow detection that the nucleic acid aptamer has high binding affinity and specificity, the microglial cells can be specifically recognized, and non-microglial cells are not recognized. The screened aptamer can be further truncated and optimized, has the advantages of small molecular weight, synthesis cost saving, affinity improvement, easy modification and transformation, no cytotoxicity, strong binding specificity, no immunogenicity and high stability, the molecular target of the aptamer for recognizing microglial cells is transmembrane protein CD64, the expression of the transmembrane protein CD64 is increased under the inflammatory stimulation of LPS and IFN-gamma, and the transmembrane protein CD64 can be used for identifying microglial cells. Therefore, the affinity of the aptamer and the microglial cells subjected to inflammatory activation is higher. Due to the advantages, the nucleic acid aptamer has important potential for diagnosis and targeted regulation of CD64 protein related diseases as a microglial cell specific recognition molecular probe.
Owner:THE EYE HOSPITAL OF WENZHOU MEDICAL UNIV
NK trophoblast cell as well as preparation method and application thereof
PendingCN112852744ASimple methodIncrease success rateNGF/TNF-superfamilyMicroorganism based processesFusion Protein ExpressionNatural Killer Cell Inhibitory Receptors
The invention provides an NK trophoblast cell as well as a preparation method and application thereof. The NK trophoblast cell expresses membrane proteins CD19, CD86, IL21, CD64 and CD137L; the IL-21 forms an IL-21-CD8[alpha] fusion protein through the IL-21 and a CD8[alpha] trans-membrane region, and the IL-21-CD8[alpha] fusion protein is expressed on the surface of the NK trophoblast cells; the CD86 comprises an amino acid sequence as shown in SEQ ID NO: 1; and the IL-21-CD8[alpha] comprises an amino acid sequence as shown in SEQ ID NO: 2. The NK trophoblast cell constructed by the invention has high expression rate on CD19, CD86, IL21, CD64 and CD137L, and the multiplication capacity of the NK cell is synergistically activated by the factors, so that the effect of inducing the NK cell to differentiate and mature in vitro is realized.
Owner:HENAN HUALONG BIOLOGICAL TECH
Method for quantitatively separating and detecting infiltrative immune cells of small intestine muscularis
ActiveCN112342193ACell dissociation methodsMicrobiological testing/measurementAntiendomysial antibodiesSmall intestine
The invention provides a separating and detecting method for the infiltrative immune cells of small intestine muscularis, and belongs to the field of immune cell separating detection. The method disclosed by the invention uses DNase I, collagenase II and I type protease at a specific ratio to carry out enzymolysis to separate cells, and then, a specific antibody combination CD45.2, CD11b, CD64, Ly6G, Ly6C and MHC II is used for carrying out screening to obtain infiltrative mononuclear cells, immature macrophages and mature macrophages. The method disclosed by the invention is the method whichcan separate maximum categories of immune cells from the small intestine muscularis in one time.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV
Estimating cellular populations
An immunoassay for assisting in the diagnosis of sepsis or severe infection in a patient / subject, the assay comprising the steps of: (i) optionally contacting a test sample comprising neutrophils fromthe patient with an agent that permeabilises or solubilises neutrophils; (ii) simultaneously with (i) or sequentially, contacting the sample with a binding agent that binds specifically to CD64 in the sample and forms a CD64-binding agent complex a; (iii) simultaneously with (i) and / or (ii) or sequentially, contacting the sample with a second binding agent that binds specifically to a neutrophilnumber marker (NNM) in the sample and forms a neutrophil marker-binding agent complex b; (iv) employ the amount of complex a and complex b to determine the relative level of CD46 and of NNM in the sample.
Owner:THE MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LTD
NK (Natural Killer) trophoblast cell for expressing cytokine composition as well as preparation method and application of NK trophoblast cell
PendingCN112779224ASimple methodIncrease success rateNucleic acid vectorNGF-receptor/TNF-receptor superfamilyNatural Killer Cell Inhibitory ReceptorsCD86
The invention provides an NK (Natural Killer) trophoblast cell for expressing a cytokine composition as well as a preparation method and application of the NK trophoblast cell. The NK trophoblast cell expresses membrane proteins CD19, CD86, IL21, CD64 and CD137L; the CD19 comprises an amino acid sequence as shown in SEQ ID NO:1; and the CD86 comprises an amino acid sequence as shown in SEQ ID NO:2. The NK trophoblast cell constructed by the invention has high expression rate on CD19, CD86, IL21, CD64 and CD137L, and the multiplication capacity of the NK cells is synergistically activated by the factors, so that the effect of inducing the NK cells to differentiate and mature in vitro is achieved.
Owner:HENAN HUALONG BIOLOGICAL TECH
Composition for detecting tumor residues of mother cell plasma cell-like dendritic cells and application of composition for detecting tumor residues of mother cell plasma cell-like dendritic cells
PendingCN114354934AImprove detection accuracyAvoid diagnostic errorsIndividual particle analysisBiological testingPlasmacytoid dendritic cellCD15
The invention provides a mother cell plasma cell-like dendritic cell tumor residue detection composition and a mother cell plasma cell-like dendritic cell tumor residue detection composition, the mother cell plasma cell-like dendritic cell tumor residue detection composition comprises a first composition and a second composition, the first composition at least comprises a CD56 antibody, a CD123 antibody, a CD34 antibody, a CD4 antibody, a CD304 antibody, an HLA-DR antibody, a CD303 antibody and a CD45 antibody, and the second composition at least comprises a first antibody and a second antibody. The composition II at least comprises a CD64 antibody, a CD123 antibody, a CD33 antibody, a CD11b antibody, an HLA-DR antibody, a CD15 antibody and a CD45 antibody. The composition provided by the invention not only can distinguish abnormal tumor cells from normal cells, but also can distinguish dendritic cells from myeloid cells, is high in detection accuracy, and can effectively avoid diagnosis errors caused by missing detection or false detection.
Owner:武汉康圣达医学检验所有限公司
Human cytolytic fusion proteins
ActiveUS20170114111A1Peptide/protein ingredientsAntibody mimetics/scaffoldsBinding siteAntibody fragments
The technology provided herein relates to novel human cytolytic fusion proteins (hCFPs) suitable to induce apoptosis in human cells comprising a target cell-specific binding component and a human effector domain, wherein the binding component comprises an antibody or an antibody fragment with an antigen-binding site for binding to the cellular surface receptor CD64 and the effector domain comprises a variant of wild type human angiogenin (Ang) or a functional fragment thereof; to nucleic acid molecules encoding said recombinant hCFPs, vectors and host cells containing said nucleic acids and methods for preparation and producing these hCFPs.
Owner:UNIVERSITY OF CAPE TOWN
Transplanted cell protection by Fc isolation
PendingCN114787351AGenetically modified cellsUnknown materialsComplement-dependent cytotoxicityCytotoxicity
The present invention provides for the first time cells comprising enhanced CD16, CD32, or CD64 expression to evade antibody dependent cytotoxicity (ADCC) or complement dependent cytotoxicity (CDC). The cells may be pluripotent cells, including low immune pluripotent cells (HIP) or ABO blood group O type rhesus factor negative HIP cells (HIPO-), which further comprise enhanced CD16, CD32, or CD64 expression. The present invention encompasses cells derived from the pluripotent cells.
Owner:RGT UNIV OF CALIFORNIA
Method for treating pulmonary exacerbation and disease progression in subjects having cystic fibrosis
ActiveUS10126295B2Short interval of exacerbation free timeHealth-index calculationMicrobiological testing/measurementDisease progressionWhole blood sample
Owner:NAT JEWISH HEALTH
Compositions and methods of enhancing Anti-tumor response using hybrid neutrophils
PendingUS20210268020A1Good curative effectOrganic active ingredientsPeptide/protein ingredientsAntiendomysial antibodiesTumor response
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com